<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Kasarla SS</submitter><pubmed_abstract>Ayurvedic medicines &lt;i>Withania somnifera&lt;/i> Dunal (&lt;i>ashwagandha&lt;/i>) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of &lt;i>Ashwagandha&lt;/i> and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb-drug interactions as &lt;i>ashwagandha&lt;/i> and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of &lt;i>ashwagandha&lt;/i> and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from &lt;i>ashwagandha&lt;/i> and AYUSH-64 extracts, respectively. In addition, &lt;i>in silico&lt;/i> studies re</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>973768</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9597875</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;i>In vitro&lt;/i> effect of &lt;i>Withania somnifera&lt;/i>, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19.</pubmed_title><pmcid>PMC9597875</pmcid><pubmed_authors>Kasarla SS</pubmed_authors><pubmed_authors>Sharma N</pubmed_authors><pubmed_authors>Kumar Y</pubmed_authors><pubmed_authors>Dikshit M</pubmed_authors><pubmed_authors>Borse SP</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>In vitro&lt;/i> effect of &lt;i>Withania somnifera&lt;/i>, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19.</name><description>Ayurvedic medicines &lt;i>Withania somnifera&lt;/i> Dunal (&lt;i>ashwagandha&lt;/i>) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of &lt;i>Ashwagandha&lt;/i> and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb-drug interactions as &lt;i>ashwagandha&lt;/i> and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of &lt;i>ashwagandha&lt;/i> and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from &lt;i>ashwagandha&lt;/i> and AYUSH-64 extracts, respectively. In addition, &lt;i>in silico&lt;/i> studies re</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-04-08T11:38:07.675Z</modification><creation>2024-11-09T20:37:10.027Z</creation></dates><accession>S-EPMC9597875</accession><cross_references><pubmed>36313313</pubmed><doi>10.3389/fphar.2022.973768</doi></cross_references></HashMap>